Highlights Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 00:00:02 05/03/2026 +03			Pre-market 17:07:18
245.30 ^USD	-0.59%		242.94	-0.96%

04:20pm	The Year the Easy Narrative Broke
01:36pm	JPMorgan Adjusts Price Target on Johnson & Johnson to $250 From $225, Maintains Neutral Rating	MT

Highlights

03-04	China commerce vice minister met with Johnson & Johnson VP	RE
03-03	Johnson & Johnson Therapy Nipocalimab Granted U.S. FDA Fast Track designation in systemic lupus erythematosus	CI
03-02	United Therapeutics' drug slows progression of rare lung condition in late-stage study	RE
02-27	Johnson & Johnson Announces Preliminary Results From Phase 1b Study Of Pasritamig In Combination With Docetaxel In Advanced Prostate Cancer	CI
02-26	Judge rejects Kenvue bid to dismiss Texas lawsuit over Tylenol safety	RE
02-26	Judge rejects Kenvue bid to dismiss Texas lawsuit over Tylenol safety	RE
02-26	Judge rejects Kenvue bid to dismiss Texas lawsuit over Tylenol	RE
02-25	Johnson & Johnson Seeks FDA Approval of IMAAVY® (nipocalimab-aahu) as the First-Ever FDA-Approved Treatment for Warm Autoimmune Hemolytic Anemia	CI
02-24	Bayer Sues Johnson & Johnson Over Alleged False Promotion of Prostate Cancer Drug	MT
02-24		FA
02-23	Bayer Files Lawsuit Against J&J, Alleging False Advertising for Prostate-Cancer Drug -- Update	DJ
02-23	Johnson & Johnson Sued by Bayer Over Alleged False Claims on NUBEQA	MT
02-23	Bayer Files Lawsuit Against J&J, Alleging False Advertising for Prostate-Cancer Drug	DJ
02-23	Bayer sues Johnson & Johnson over claim that prostate cancer drug cuts risk of death	RE
02-23	Johnson & Johnson Sued by Bayer Over Alleged False Claims on NUBEQA	MT
02-23	Johnson & Johnson Sued by Bayer for Alleged False Claims on NUBEQA	MT
02-23	Johnson & Johnson Sued by Bayer Over Alleged False Claims Regarding Nubeqa's Efficacy	MT
02-23	EU Commission OKs New Dosing Options for J&J's Non-small Lung Cancer Treatment	MT
02-23	Bayer files lawsuit against Johnson & Johnson, Janssen Biotech	RE
02-23	Gossamer Bio shares plummet as lung disease drug fails late-stage trial	RE
02-23	Blackstone Life Sciences and Johnson & Johnson Announces A Co-Funding Agreement for Acute Myeloid Leukemia	CI
02-23	Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion	RE
02-21	Johnson & Johnson Announces New Long-Term Data from the Quasar Long-Term Extension Study	CI
02-21	US FDA approves Vanda's antipsychotic pill, shares climb	RE
02-20	Novartis to Divest Majority Stake in India Arm Amid Tariff Threats	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

J&J CFO Wolk on Orthopedics Spinoff, Earnings, Drug Pricing

October 14, 2025 at 07:20 pm

Johnson & Johnson: A Dose of Resilience Amid Trade Tensions

April 15, 2025 at 04:53 pm